MA28092A1 - Anticorps diriges contre un m-csf - Google Patents
Anticorps diriges contre un m-csfInfo
- Publication number
- MA28092A1 MA28092A1 MA28927A MA28927A MA28092A1 MA 28092 A1 MA28092 A1 MA 28092A1 MA 28927 A MA28927 A MA 28927A MA 28927 A MA28927 A MA 28927A MA 28092 A1 MA28092 A1 MA 28092A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- csf
- relates
- nucleic acid
- acid molecules
- Prior art date
Links
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 title 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/06—Buying, selling or leasing transactions
- G06Q30/0601—Electronic shopping [e-shopping]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
- G06Q40/04—Trading; Exchange, e.g. stocks, commodities, derivatives or currency exchange
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/12—Hotels or restaurants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Business, Economics & Management (AREA)
- Immunology (AREA)
- Finance (AREA)
- Accounting & Taxation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Strategic Management (AREA)
- Physical Education & Sports Medicine (AREA)
- General Business, Economics & Management (AREA)
- Development Economics (AREA)
- Economics (AREA)
- Marketing (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Tourism & Hospitality (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
Abstract
La présente invention se rapporte à des anticorps et à leurs parties de liaison à des antigènes qui se lient spécifiquement à un M-CSF, de préférence un M-CSF humain, et qui fonctionnent de manière a inhiber un M-CSF. L'invention se rapporte également à des anticorps anti-M-CSF et à leurs parties de liaison à des antigènes. L'invention se rapporte aussi à des anticorps qui sont des anticorps chimériques, bispécifiques, dérivatisés et à chaîne simple ou des parties de protéines de fusion. L'invention se rapporte également à des immunoglobulines isolées à chaînes lourdes et légères dérivées d'anticorps anti-M-CSF humains et de molécules d'acides nucléiques codant ces immunoglobulines. La présente invention se rapporte également à des procédés d'élaboration d'anticorps anti-M-CSF humains, à des compositions comportant des anticorps et à des procédés d'utilisation de ces anticorps et compositions à des fins diagnostiques et thérapeutiques. L'invention se rapporte également à des méthodes de thérapie génique utilisant des molécules d'acides nucléiques codant les molécules d'immunoglobulines à chaînes lourdes et/ou légères qui comprennent ces anticorps anti-M-CSF humains. L'invention se rapporte en outre à des animaux transgéniques et à des plantes transgéniques comportant les molécules d'acides nucléiques décrites ci-dessus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50216303P | 2003-09-10 | 2003-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28092A1 true MA28092A1 (fr) | 2006-08-01 |
Family
ID=33300142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28927A MA28092A1 (fr) | 2003-09-10 | 2006-04-10 | Anticorps diriges contre un m-csf |
Country Status (42)
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091451A1 (en) * | 2002-11-15 | 2011-04-21 | Kavanaugh William M | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
SI1819358T1 (sl) * | 2004-11-18 | 2014-10-30 | Imclone Llc | Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1) |
BRPI0608815B1 (pt) * | 2005-03-08 | 2021-10-13 | Pfizer Products Inc | Composições de anticorpo anti-ctla-4 |
EP1858928A2 (fr) * | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits |
WO2007016240A2 (fr) * | 2005-07-28 | 2007-02-08 | Novartis Ag | Utilisation d'anticorps anti-m-csf |
WO2007016285A2 (fr) * | 2005-07-28 | 2007-02-08 | Novartis Ag | Anticorps monoclonal specifique de m-csf et ses utilisations |
JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EP2118139A1 (fr) * | 2007-02-06 | 2009-11-18 | Ribovax Biotechnologies SA | Anti-corps destines particulierement au virus de la varicelle et du zona |
KR101770429B1 (ko) * | 2007-08-21 | 2017-08-22 | 암젠 인코퍼레이티드 | 인간 c-fms 항원 결합 단백질 |
US20090104148A1 (en) * | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
ES2526355T3 (es) | 2007-10-01 | 2015-01-09 | Bristol-Myers Squibb Company | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos |
JP2011502266A (ja) * | 2007-10-31 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Fms治療に対する応答を評価するバイオマーカー |
CN101970489B (zh) * | 2007-11-13 | 2014-06-11 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
WO2009086920A1 (fr) * | 2008-01-04 | 2009-07-16 | Baxter International Inc. | Anticorps anti-mif |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
NZ587830A (en) | 2008-03-14 | 2012-08-31 | Transgene Sa | Antibody against the colony-stimulating factor-1 receptor (CSF-1R) |
JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
DK2406290T3 (en) | 2009-03-10 | 2017-09-11 | Baylor Res Inst | CANCER VACCINES TARGETED FOR ANTIGEN PRESENTING CELLS |
BRPI1009455A2 (pt) | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
AU2010226392B9 (en) | 2009-03-20 | 2014-05-22 | Amgen Inc. | Selective and potent peptide inhibitors of Kv1.3 |
CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
EP2470561A1 (fr) | 2009-08-27 | 2012-07-04 | Novo Nordisk A/S | Ciblage du facteur tissulaire sur des plaquettes activées |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
WO2011053665A1 (fr) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Immunodosage de pcsk9 |
WO2011140249A2 (fr) * | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Anticorps liant csf1r |
LT3789038T (lt) * | 2010-05-14 | 2022-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47 |
CN103108658B (zh) | 2010-07-02 | 2015-08-19 | 米迪缪尼有限公司 | 抗体制剂 |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
AU2015234335B2 (en) * | 2010-09-29 | 2017-09-28 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
WO2012047724A1 (fr) * | 2010-09-29 | 2012-04-12 | Agensys, Inc. | Conjugués anticorps-médicaments (adc) se liant aux protéines 191p4d12 |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
AU2012285875B2 (en) | 2011-07-18 | 2016-11-10 | Morphosys Ag | Use of c-Fms antagonists |
MX2014005570A (es) * | 2011-11-08 | 2014-05-30 | Pfizer | El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios. |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
JO3623B1 (ar) * | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (fr) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt |
KR20150140752A (ko) * | 2013-04-12 | 2015-12-16 | 모르포시스 아게 | M-csf를 표적으로 하는 항체 |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
WO2015089073A2 (fr) * | 2013-12-09 | 2015-06-18 | New York University | Compositions et méthodes utilisées pour administrer des agents anti-staphylococciques par phagocytose |
US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
EP3143404B1 (fr) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Dosage pour la détection de populations de cellules th1 et th2 |
CN113350501A (zh) | 2014-06-23 | 2021-09-07 | 戊瑞治疗有限公司 | 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
TW201632202A (zh) | 2015-01-30 | 2016-09-16 | 諾華公司 | 乳癌之治療 |
WO2016137985A1 (fr) | 2015-02-26 | 2016-09-01 | Merck Patent Gmbh | Inhibiteurs de pd-1/pd-l1 pour le traitement du cancer |
WO2016205277A1 (fr) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Polythérapies faisant intervenir un antagoniste de pd-l1 |
BR112018068340A2 (pt) | 2016-03-11 | 2019-01-15 | Scholar Rock Inc | imunoglobulinas de ligação ao tgfss1 e usos destas |
BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Merck Patent Gmbh | regime de dosagem de avelumabe para o tratamento de câncer |
PE20191661A1 (es) * | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
US20200131518A1 (en) | 2017-03-14 | 2020-04-30 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
EP3694545A4 (fr) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | Anticorps pd-l1 humains et leurs procédés d'utilisation |
US11802146B2 (en) | 2018-01-05 | 2023-10-31 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
AU2019228381B2 (en) | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
CA3092695A1 (fr) | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Anticorps anti-pd-l2 humains et leurs procedes d'utilisation |
WO2019182896A1 (fr) * | 2018-03-23 | 2019-09-26 | Board Of Regents, The University Of Texas System | Anticorps à double spécificité pour pd-l1 et pd-l2 et leurs procédés d'utilisation |
MA52186A (fr) | 2018-03-26 | 2021-02-17 | Amgen Inc | Glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
CA3100829A1 (fr) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Anticorps specifiques de gucy2c et leurs utilisations |
PE20210127A1 (es) | 2018-05-23 | 2021-01-19 | Pfizer | Anticuerpos especificos para cd3 y sus usos |
WO2020014358A1 (fr) | 2018-07-10 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Modification de molécules de liaison pour réduire au minimum des interactions préexistantes |
WO2020044252A1 (fr) | 2018-08-31 | 2020-03-05 | Novartis Ag | Régimes posologiques pour anticorps anti-m-csf et utilisations associées |
WO2020128893A1 (fr) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Traitements combinés de cancer comprenant un agoniste de tlr |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
MX2022003461A (es) | 2019-09-26 | 2022-04-19 | Amgen Inc | Metodos de produccion de composiciones de anticuerpos. |
EP4077387A1 (fr) | 2019-12-17 | 2022-10-26 | Pfizer Inc. | Anticorps spécifiques pour cd47, pd-l1, et leurs utilisations |
ES2969732T3 (es) | 2019-12-18 | 2024-05-22 | Pfizer | Régimen de tratamiento del cáncer una vez al día con un inhibidor de PRMT5 |
JP7481856B2 (ja) * | 2020-02-25 | 2024-05-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
CA3174908A1 (fr) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Proteines de fusion et leurs utilisations |
US20230192878A1 (en) | 2020-05-13 | 2023-06-22 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
WO2021247892A1 (fr) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique |
JP2023533793A (ja) | 2020-07-17 | 2023-08-04 | ファイザー・インク | 治療用抗体およびそれらの使用 |
WO2022053990A1 (fr) | 2020-09-14 | 2022-03-17 | Pfizer Inc. | Procédés, thérapies et utilisations pour le traitement du cancer |
CA3197930A1 (fr) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Glycanes relatifs non apparies dans des procedes de production d'anticorps |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
WO2022153161A1 (fr) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Traitement du cancer à l'aide d'un inhibiteur de prmt5 |
US20240228668A1 (en) * | 2021-02-26 | 2024-07-11 | New York University | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
CA3222409A1 (fr) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Utilisation de fucosidase pour controler le taux d'afucosylation de proteines glycosylees |
CA3233279A1 (fr) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Liaison de recepteur fc-gamma et teneur en glycane |
WO2023215725A1 (fr) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions et méthodes pour l'immunothérapie cellulaire |
WO2023218320A1 (fr) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation |
WO2023242769A1 (fr) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Variants d'il-12, anticorps anti-pd1, protéines de fusion et leurs utilisations |
WO2024003773A1 (fr) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | Composés de 2,7-naphtyridine en tant qu'inhibiteurs de mastl |
WO2024009191A1 (fr) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Composés pyrido[4,3-d]pyrimidines |
WO2024074977A1 (fr) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Composés 1h-pyrazolo-pyridine et -pyrimidine substitués |
WO2024084364A1 (fr) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Composés pour le traitement du cancer |
WO2024105563A1 (fr) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Dérivés de pyridone bicyclique substitués |
Family Cites Families (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5531159A (en) | 1978-08-26 | 1980-03-05 | Sumitomo Metal Ind Ltd | Manufacture of high strength cold rolled steel plate for press working |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4504586A (en) * | 1983-02-03 | 1985-03-12 | Amgen | Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1 |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5573930A (en) | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
US5792450A (en) | 1985-02-05 | 1998-08-11 | Chiron Corporation | Purified human CSF-1 |
US4847201A (en) | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
US6146851A (en) | 1985-02-05 | 2000-11-14 | Chiron Corporation | DNA encoding NV2 (long form) and carboxy truncated fragments thereof |
US5837229A (en) | 1985-02-05 | 1998-11-17 | Chiron Corporation | Uses of recombinant colony stimulating factor-1 |
DE3689391T2 (de) | 1985-02-05 | 1994-06-30 | Cetus Oncology Corp., Emeryville, Calif. | Rekombinanter koloniestimulierender faktor-1. |
AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4868119A (en) | 1986-12-11 | 1989-09-19 | Genetics Institute, Inc. | Hematopoietic growth factors |
WO1987006954A1 (fr) | 1986-05-06 | 1987-11-19 | Genetics Institute, Inc. | Production de m-csf |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
CA1339757C (fr) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Methode de production bacteriologique de csf-1 humain recombinant biologiquement actif pur |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4929455A (en) * | 1988-07-07 | 1990-05-29 | Mallinckrodt, Inc. | Flour-based pot pie crusts with improved texture |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DK0457804T3 (da) * | 1989-02-10 | 1996-09-23 | Chiron Corp | M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop |
KR920701246A (ko) | 1989-07-14 | 1992-08-11 | 스타이나 브이. 칸스타드 | 카르복실 말단으로부터 유도된 gm-csf의 길항제 |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
JPH05503098A (ja) * | 1989-12-15 | 1993-05-27 | カイロン コーポレイション | セプシスの処理のためのサイトカイン抗体 |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (fr) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003917A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International | Recombinaison homologue dans des cellules de mammiferes |
EP0546073B1 (fr) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2060741A1 (fr) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Oligopeptides inhibant le gm-csf |
WO1992015677A1 (fr) | 1991-03-01 | 1992-09-17 | Protein Engineering Corporation | Procede de developpement de mini-proteines de liaison |
ES2223040T3 (es) | 1991-04-10 | 2005-02-16 | The Scripps Research Institute | Bibliotecas de receptor heterodimerilo que usan fagemidos. |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
JPH0595794A (ja) * | 1991-10-04 | 1993-04-20 | Otsuka Pharmaceut Co Ltd | ヒトm−csf抗体及びヒトm−csfの測定法 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0618970A1 (fr) | 1991-12-10 | 1994-10-12 | Dana Farber Cancer Institute | Anticorps recombine humain anti-gp120 neutralisant le reactif, adn codant celui-ci et son utilisation |
JPH067189A (ja) | 1991-12-17 | 1994-01-18 | Morinaga Milk Ind Co Ltd | ヒトM−CSF β型ダイマ−に特異性を有するモノクロ− ナル抗体と、この抗体を産生するハイブリドーマ、お よびこの抗体の利用 |
CA2129663C (fr) | 1992-02-06 | 2005-07-05 | James S. Huston | Proteine fixatrice biosynthetique pour marqueur du cancer |
ATE195553T1 (de) * | 1992-06-09 | 2000-09-15 | Chiron Corp | Kristallisierung von m-csf |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
JP3714683B2 (ja) | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
JPH06194367A (ja) | 1992-12-25 | 1994-07-15 | Morinaga Milk Ind Co Ltd | リウマチ疾患の診断方法 |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
WO1994019935A1 (fr) | 1993-03-09 | 1994-09-15 | Genzyme Corporation | Isolement de constituants d'interet du lait |
JPH06319584A (ja) | 1993-05-07 | 1994-11-22 | Morinaga Milk Ind Co Ltd | 抗m−csfモノクロ−ナル抗体と、この抗体を産生 するハイブリド−マ |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
WO1995029690A1 (fr) | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Peptides biologiquement actifs et procedes permettant leur identification |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
WO1996033266A1 (fr) | 1995-04-21 | 1996-10-24 | Cell Genesys, Inc. | Creation d'importantes deletions d'adn genomique |
CA2761116A1 (fr) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Anticorps humains derives d'une xenosouris immunisee |
CA2219486A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
EP0818442A3 (fr) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs |
WO1998002437A1 (fr) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
PT923585E (pt) | 1996-07-18 | 2002-08-30 | Pfizer | Inibidores a base de fosfinato de metaloproteases de matriz |
WO1998007697A1 (fr) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Derives de l'acide arylsulfonylamino hydroxamique |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (ko) * | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
ES2224277T3 (es) | 1997-01-06 | 2005-03-01 | Pfizer Inc. | Derivados de sulfonas ciclicas. |
DK0977733T3 (da) | 1997-02-03 | 2003-11-24 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsyrederivater |
EP0966438A1 (fr) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices |
KR20000070923A (ko) | 1997-02-11 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐 하이드록삼산 유도체 |
AU6702998A (en) | 1997-03-12 | 1998-09-29 | Smithkline Beecham Corporation | Anti-alphabeta3 humanized monoclonal antibodies |
EP2336168A1 (fr) * | 1997-04-15 | 2011-06-22 | Sankyo Company Limited | Nouvelle protéine et et procédé pour le produire |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2239393T3 (es) | 1997-05-07 | 2005-09-16 | Sugen, Inc. | Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa. |
EP0983303B1 (fr) | 1997-05-21 | 2006-03-08 | Biovation Limited | Procede de production de proteines non immunogenes |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
EA002490B1 (ru) | 1997-08-08 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилоксиарилсульфониламиногидроксамовой кислоты |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
EP1017682A4 (fr) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Nouveaux inhibiteurs de l'angiogenese |
JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
EP1082305A4 (fr) | 1998-05-29 | 2001-09-26 | Sugen Inc | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
ES2213985T3 (es) | 1998-11-05 | 2004-09-01 | Pfizer Products Inc. | Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico. |
ES2278463T3 (es) | 1998-12-08 | 2007-08-01 | Biovation Limited | Metodo para reducir la inmunogenicidad de proteinas. |
AU1687500A (en) * | 1998-12-16 | 2000-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Antihuman vegf monoclonal antibody |
KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6471429B1 (en) * | 1999-01-29 | 2002-10-29 | Canon Kabushiki Kaisha | Sheet processing apparatus for discharging sheets in a bundle |
AU5761900A (en) | 1999-06-30 | 2001-01-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120 |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
WO2001034177A2 (fr) | 1999-11-08 | 2001-05-17 | The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health | Procede pour le traitement d'une infection virale a l'aide d'antagonistes du facteur stimulant la proliferation de macrophages |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
EP1285084A1 (fr) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides |
US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
EP3190126A1 (fr) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Utilisation d'anticorps contre le recepteur d'interleukine-4 (il-4r) et compositions correspondantes |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
WO2002002641A1 (fr) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
WO2002059340A1 (fr) | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Immunopolypeptides diriges contre le virus de l'hepatite c |
MXPA03007144A (es) | 2001-02-12 | 2004-04-02 | Medarex Inc | Anticuerpos monoclonales humanos para receptor fc alfa (cd89). |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
EP2011802A3 (fr) | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anticorps monoclonal anti-CD40 |
JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗cd40モノクローナル抗体 |
JP2005168497A (ja) | 2001-05-18 | 2005-06-30 | Kirin Brewery Co Ltd | 抗trail−r抗体およびその用途 |
FI112501B (fi) | 2001-05-18 | 2003-12-15 | Valtion Teknillinen | Heveiiniä sitovat monoklonaaliset vasta-aineet |
AU2002256895B2 (en) | 2001-05-18 | 2008-09-18 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
PT1410011E (pt) | 2001-06-18 | 2011-07-25 | Rosetta Inpharmatics Llc | Diagnóstico e prognóstico de pacientes com cancro da mama |
JP4190005B2 (ja) | 2001-08-22 | 2008-12-03 | 株式会社抗体研究所 | 結合性分子の選択方法 |
WO2003033538A1 (fr) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anticorps anti-hlr-dr |
JP3729841B2 (ja) | 2001-10-15 | 2005-12-21 | 麒麟麦酒株式会社 | 抗hla−dr抗体の利用 |
WO2003055979A2 (fr) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Anticorps se liant à blys selon un mode immunospécifique |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
WO2003048328A2 (fr) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix) |
EP1322146A1 (fr) | 2001-12-18 | 2003-06-25 | Phoenix Precision Technology Corporation | Méthode de dépôt électrolytique de bosses de soudure sur une carte de circuits imprimés organique |
CA2471702C (fr) | 2002-01-09 | 2013-03-19 | Medarex, Inc. | Anticorps monoclonaux humains contre cd30 |
WO2003070752A2 (fr) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Ligands de liaison au complexe mhc-peptide |
PT1490405E (pt) | 2002-03-21 | 2007-11-07 | Lilly Co Eli | Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos |
WO2003091413A2 (fr) | 2002-04-23 | 2003-11-06 | The Scripps Research Institute | Expression de polypeptides dans des chloroplastes, et compositions et procedes permettant de les exprimer |
DE60332011D1 (de) | 2002-04-29 | 2010-05-20 | Sanquin Bloedvoorziening | Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein") |
WO2004024750A2 (fr) | 2002-09-13 | 2004-03-25 | Dyax Corporation | Ligands liant cd44 |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
PL217296B1 (pl) | 2002-11-15 | 2014-07-31 | Genmab As | Wyizolowane ludzkie przeciwciało monoklonalne, wytwarzająca je hybrydoma, kodujący to przeciwciało wektor ekspresyjny i zawierająca je kompozycja farmaceutyczna, immunokoniugat, bispecyficzna lub multispecyficzna cząsteczka obejmująca kwasy nukleinowe kodujące ciężki i lekki łańcuch transfektoma, ich zastosowania, zwłaszcza w medycynie, obejmująca te kwasy ex vivo eukariotyczna lub prokariotyczna komórka gospodarza oraz nie będące człowiekiem zwierzę transgeniczne lub roślina, sposób in vitro hamowania wzrostu i/lub proliferacji komórek wyrażających CD25 lub eliminowania komórek wyrażających CD25, sposób wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25, zestaw diagnostyczny do wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25 |
CN1787837A (zh) * | 2002-11-15 | 2006-06-14 | 希龙公司 | 防止和治疗癌转移以及与癌转移相关的骨质损失的方法 |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
JP2006517188A (ja) * | 2002-12-02 | 2006-07-20 | アブジェニックス・インコーポレーテッド | ホスホリパーゼa2に対する抗体及びその使用 |
US20050013809A1 (en) | 2002-12-02 | 2005-01-20 | Owens Samuel M. | Antibodies against drugs of abuse |
WO2005035732A2 (fr) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Ligands de papp-a |
CA2519528C (fr) * | 2003-03-19 | 2016-01-26 | Abgenix, Inc. | Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations |
KR20060035599A (ko) | 2003-05-06 | 2006-04-26 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 크립토코커스증 치료용 조성물 및 방법 |
EP1627062A1 (fr) | 2003-05-14 | 2006-02-22 | Domantis Limited | Procede de recuperation de polypeptides qui se deplient de facon reversible a partir d'un repertoire de polypeptides |
MXPA05012571A (es) | 2003-05-21 | 2006-02-08 | Medarex Inc | Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis. |
WO2004108078A2 (fr) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Anticorps conçus de maniere rationnelle |
EA030259B8 (ru) | 2003-07-15 | 2018-09-28 | Амджен Инк. | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf |
KR101215218B1 (ko) | 2003-07-22 | 2012-12-26 | 바이엘 파마 악티엔게젤샤프트 | Rg1 항체 및 그의 용도 |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
WO2005019267A2 (fr) | 2003-08-12 | 2005-03-03 | Dyax Corp. | Ligands se fixant au tie 1 |
EP1660537A2 (fr) | 2003-08-14 | 2006-05-31 | Dyax Corp. | Ligands de l'endotheliase-2 |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
JP2007510622A (ja) | 2003-10-08 | 2007-04-26 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 |
CA2543631A1 (fr) | 2003-11-07 | 2005-05-26 | Amgen Inc. | Sequences d'immunoglobuline de singes |
AU2004290017B2 (en) | 2003-11-07 | 2012-05-03 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
AU2004298492B2 (en) | 2003-12-10 | 2011-08-18 | E. R. Squibb & Sons, L.L.C. | IP-10 antibodies and their uses |
DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
JP4712724B2 (ja) | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | CD1aに対するヒト結合分子 |
DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
NZ548821A (en) | 2004-02-06 | 2009-12-24 | Univ Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2005086713A2 (fr) | 2004-03-04 | 2005-09-22 | Kirin Brewery Co., Ltd. | Role des precurseurs de cellules endotheliales humaines et des pericytes vasculaires dans l'angiogenese d'une tumeur |
WO2005092926A2 (fr) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reduction du risque d'anticorps humains et anti-humains par la manipulation du gene v |
SG172616A1 (en) * | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
WO2005109266A1 (fr) | 2004-05-07 | 2005-11-17 | Snap-On Incorporated | Systeme de surveillance d'outils |
ES2563491T3 (es) | 2004-07-06 | 2016-03-15 | Bioren, LLC | Bibliotecas universales de anticuerpos |
WO2006020258A2 (fr) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Nouveau anticorps bispecifique tetravalent |
MX2007000644A (es) | 2004-07-20 | 2007-03-28 | Symphogen As | Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion. |
WO2006017538A2 (fr) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Proteines de liaison a la proteine hk1 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
WO2006017759A2 (fr) | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Anticorps fixant le marqueur specifique des cellules endotheliales (tem1) et leurs utilisations |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
KR20070085236A (ko) | 2004-08-23 | 2007-08-27 | 메다렉스, 인코포레이티드 | 뉴몰리신에 대한 결합원 |
JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
EP1802345A2 (fr) | 2004-10-01 | 2007-07-04 | Medarex, Inc. | Procede pour traiter des lymphomes positifs cd30 |
KR100619546B1 (ko) | 2004-10-05 | 2006-09-04 | 아주대학교산학협력단 | 히스톤 h2a 및/또는 h2b에 대한 인간 모노클로날자가항체 및 그 단편 |
SI1819358T1 (sl) | 2004-11-18 | 2014-10-30 | Imclone Llc | Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1) |
EP2842571A1 (fr) | 2004-11-30 | 2015-03-04 | Celldex Therapeutics, Inc. | Anticorps diriges contre la GPNMB et leurs utilisations |
WO2006068953A2 (fr) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
EP1851245B1 (fr) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Anticorps dirigés contre l'interleukine-1 beta |
KR101323455B1 (ko) | 2005-02-18 | 2013-10-29 | 메다렉스, 엘.엘.시. | 푸코실 잔기가 결여된 cd30에 대한 단클론 항체 |
BRPI0608815B1 (pt) | 2005-03-08 | 2021-10-13 | Pfizer Products Inc | Composições de anticorpo anti-ctla-4 |
EP1858928A2 (fr) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits |
AU2005333155B2 (en) | 2005-03-14 | 2011-11-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
CA2605964A1 (fr) | 2005-04-20 | 2006-10-26 | Amgen Fremont Inc. | Anticorps monoclonaux entierement humains a affinite elevee d'interleukine-8 et epitopes destines a ces anticorps |
WO2006124269A2 (fr) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
WO2007016240A2 (fr) | 2005-07-28 | 2007-02-08 | Novartis Ag | Utilisation d'anticorps anti-m-csf |
WO2007016285A2 (fr) | 2005-07-28 | 2007-02-08 | Novartis Ag | Anticorps monoclonal specifique de m-csf et ses utilisations |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
DOP2006000195A (es) * | 2005-09-07 | 2017-08-15 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
KR101460477B1 (ko) | 2013-06-18 | 2014-11-10 | 주식회사 엘지화학 | 연신 적층체, 박형 편광자의 제조 방법, 이를 이용하여 제조되는 박형 편광자 및 이를 포함하는 편광판 |
JP6319584B2 (ja) | 2015-02-27 | 2018-05-09 | 京セラドキュメントソリューションズ株式会社 | 画像形成システム |
-
2004
- 2004-09-02 AR ARP040103147A patent/AR045563A1/es active IP Right Grant
- 2004-09-07 MY MYPI20043614A patent/MY157376A/en unknown
- 2004-09-08 TW TW093127189A patent/TWI356063B/zh not_active IP Right Cessation
- 2004-09-08 TW TW098140349A patent/TWI365883B/zh not_active IP Right Cessation
- 2004-09-09 CA CA2885172A patent/CA2885172C/fr not_active Expired - Fee Related
- 2004-09-09 BR BRPI0414269A patent/BRPI0414269B8/pt not_active IP Right Cessation
- 2004-09-09 ES ES04809712.5T patent/ES2618526T3/es active Active
- 2004-09-09 PA PA20048611701A patent/PA8611701A1/es unknown
- 2004-09-09 KR KR1020067006880A patent/KR100899213B1/ko active IP Right Grant
- 2004-09-09 DK DK04809712.5T patent/DK1670825T3/en active
- 2004-09-09 ZA ZA200601969A patent/ZA200601969B/en unknown
- 2004-09-09 EP EP16201588.7A patent/EP3170840B1/fr active Active
- 2004-09-09 HN HN2004000356A patent/HN2004000356A/es unknown
- 2004-09-09 AU AU2004275700A patent/AU2004275700B2/en not_active Ceased
- 2004-09-09 UA UAA200603154A patent/UA90457C2/ru unknown
- 2004-09-09 NZ NZ584945A patent/NZ584945A/en unknown
- 2004-09-09 GE GEAP20049338A patent/GEP20104922B/en unknown
- 2004-09-09 UY UY28507A patent/UY28507A1/es not_active Application Discontinuation
- 2004-09-09 CN CN200480028051XA patent/CN1863817B/zh not_active Expired - Fee Related
- 2004-09-09 ES ES16201588T patent/ES2709700T3/es active Active
- 2004-09-09 CA CA2537876A patent/CA2537876C/fr not_active Expired - Fee Related
- 2004-09-09 KR KR1020087015841A patent/KR100938452B1/ko active IP Right Grant
- 2004-09-09 PT PT48097125T patent/PT1670825T/pt unknown
- 2004-09-09 WO PCT/US2004/029390 patent/WO2005030124A2/fr active Application Filing
- 2004-09-09 NZ NZ595450A patent/NZ595450A/xx unknown
- 2004-09-09 AP AP2006003562A patent/AP2006003562A0/xx unknown
- 2004-09-09 JP JP2006526276A patent/JP2007528724A/ja not_active Withdrawn
- 2004-09-09 NZ NZ546369A patent/NZ546369A/en unknown
- 2004-09-09 PL PL04809712T patent/PL1670825T3/pl unknown
- 2004-09-09 EP EP04809712.5A patent/EP1670825B9/fr active Active
- 2004-09-09 EA EA200600558A patent/EA011669B1/ru not_active IP Right Cessation
- 2004-09-09 GT GT200400181A patent/GT200400181A/es unknown
- 2004-09-09 PE PE2004000873A patent/PE20050376A1/es active IP Right Grant
- 2004-09-09 MX MX2012002136A patent/MX346194B/es unknown
- 2004-09-09 RS YUP-2006/0171A patent/RS20060171A/sr unknown
- 2004-09-09 CN CN201210133918.4A patent/CN102807617B/zh not_active Expired - Fee Related
- 2004-09-09 SI SI200432380T patent/SI1670825T1/sl unknown
- 2004-09-09 NL NL1027009A patent/NL1027009C2/nl not_active IP Right Cessation
- 2004-09-09 MX MXPA06002825A patent/MXPA06002825A/es unknown
- 2004-09-09 SG SG2011081270A patent/SG176457A1/en unknown
- 2004-09-09 HU HUE04809712A patent/HUE033708T2/en unknown
- 2004-09-09 GB GB0420044A patent/GB2405873A/en not_active Withdrawn
- 2004-09-09 US US10/938,353 patent/US7592430B2/en active Active
- 2004-09-09 SG SG200716760-4A patent/SG136945A1/en unknown
-
2006
- 2006-03-01 IL IL174016A patent/IL174016A/en active IP Right Grant
- 2006-03-07 IS IS8342A patent/IS3021B/is unknown
- 2006-03-10 TN TNP2006000080A patent/TNSN06080A1/en unknown
- 2006-03-13 US US11/375,221 patent/US7326414B2/en active Active
- 2006-03-28 CR CR8317A patent/CR8317A/es not_active Application Discontinuation
- 2006-04-07 NO NO20061603A patent/NO343557B1/no not_active IP Right Cessation
- 2006-04-10 EC EC2006006497A patent/ECSP066497A/es unknown
- 2006-04-10 MA MA28927A patent/MA28092A1/fr unknown
- 2006-12-20 HK HK06113986.3A patent/HK1093212A1/xx not_active IP Right Cessation
-
2007
- 2007-08-20 US US11/894,560 patent/US7728113B2/en not_active Expired - Fee Related
- 2007-10-09 JP JP2007263538A patent/JP2008067710A/ja active Pending
-
2010
- 2010-03-29 US US12/748,602 patent/US8188249B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 JP JP2011010778A patent/JP2011083291A/ja active Pending
-
2012
- 2012-04-27 US US13/458,820 patent/US20120244167A1/en not_active Abandoned
-
2013
- 2013-06-04 HK HK13106536.3A patent/HK1178921A1/xx not_active IP Right Cessation
- 2013-07-16 JP JP2013147604A patent/JP5829653B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-19 IL IL237323A patent/IL237323A0/en active IP Right Grant
- 2015-02-19 IL IL237324A patent/IL237324A0/en active IP Right Grant
- 2015-05-12 JP JP2015097050A patent/JP6106711B2/ja not_active Expired - Fee Related
- 2015-10-27 US US14/923,655 patent/US9718883B2/en active Active
-
2016
- 2016-10-18 JP JP2016204288A patent/JP6412903B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-05 US US15/614,237 patent/US10280219B2/en active Active
-
2019
- 2019-03-15 US US16/354,615 patent/US20190202905A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28092A1 (fr) | Anticorps diriges contre un m-csf | |
MA28430B1 (fr) | Anticorps a madcam. | |
MA29524B1 (fr) | Anticorps diriges contre la myostatine | |
AP1918A (en) | Antibodies to CD40 | |
TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
HK1070907A1 (en) | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same | |
WO2008019290A3 (fr) | Anticorps anti-erbb2 | |
MA48241A1 (fr) | Anticorps dirigés contre madcam |